Address: 4, Malaya Dmitrovka Str., App. 5, 127006, Moscow,Russia
Tel: +7 (495) 956-13-87
Web: http://www.acto-Russia.org/
The Association of Clinical Trials Organizations was established at the end of November 2007 as a non-commercial organization of companies engaged in clinical trials in Russia. The situation involving the export of biological samples, which occurred in May 2007, was the stimulus that led companies to create ACTO. At that time there was a lack of a uniting power to appeal on behalf of business.
The primary objectives of ACTO are to further develop Russia as clinical research market; to ensure a proper and effective balance between the interests of parties involved in clinical trials including the patients, the medical community, and the governmental agencies; to harmonize local legislative basis for the clinical trials with the respective worldwide standards; and to promote an ethical business model.
ACTO’s members conduct clinical trials in accordance with international standard of Good Clinical Practice (ICH GCP). According to the Statutes of the Association, ACTO’s members should follow the principles of integrity and respect for other market participants, and refrain from unfair competition.
ACTO represents in Russia the world’s leading pharmaceutical companies and contract research organizations. To date ACTO’s members are 26 companies: Almedis, Amgen, Bayer Schering Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, ClinStar, Covance, Cromos Pharma, Eli Lilly, i3, ICON, Janssen Pharmaceutica, Kendle, MB Quest, Medpace, Novartis, Novo Nordisk, Parexel, Pfizer, PharmaNet, PPD, PRA International, PSI, Quintiles, Servier, WCT. Now ACTO consolidates about 40% of clinical trials in Russia.
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here
